Advaxis

Advaxis was an American biotechnology company focused on the discovery, development, and potential commercialization of cancer immunotherapies. Its research was built around an engineered form of attenuated Listeria monocytogenes, generally described as an Lm-LLO platform. The bacterial vector was designed to enter important components of the immune system and secrete a fusion protein combining a tumor-associated antigen with an immune-stimulating adjuvant. The intended result was to activate T-cell responses against cells carrying the selected antigen while also weakening some of the defenses that tumors use to avoid immune attack. The company’s best-known development program was ADXS-HPV, an investigational therapy directed at cancers and precancerous conditions associated with human papillomavirus. The program was studied in indications including cervical intraepithelial neoplasia, cervical cancer, and HPV-associated head and neck cancer. Advaxis reported early clinical work in patients with metastatic, recurrent, or refractory cervical cancer, and the first Phase 1 results were published in 2009. The company also pursued additional Lm-LLO constructs for other oncology applications, including breast cancer and personalized approaches based on individual tumor antigens. Public descriptions indicated that the broader pipeline included more than fifteen constructs at different development stages, either internally or through collaborations. Advaxis operated primarily as a clinical-stage biotechnology business rather than as a company with an established portfolio of approved medicines. Its development model depended on clinical research, strategic partnerships, institutional collaborations, and access to capital markets. Collaborating organizations mentioned in connection with its platform included the National Cancer Institute, Cancer Research UK, the Wistar Institute, the University of Pennsylvania, and the United States Department of Homeland Security. The company also explored veterinary applications, including a Phase 1 study of an Lm-LLO-based immunotherapy in canine osteosarcoma. In 2014, Advaxis entered a co-development and commercialization agreement with Biocon covering ADXS-HPV in India, where HPV-associated cancers, including cervical cancer, represented a target market. Advaxis later underwent major corporate changes. The company had originally become associated with the public shell Great Expectations in 2004, which subsequently changed its name to Advaxis and later reincorporated in Delaware. In the early 2020s, the company pursued corporate transactions that affected its independent identity and capital structure. The relevant later transaction was a merger with Ayala Pharmaceuticals, after which the combined company began operating under the Ayala Pharmaceuticals name in January 2023. Advaxis is therefore best treated as a former biotechnology company and historical development brand, rather than as an independent active operating company.

Advaxis’s official date of inception was 1 March 2002. Its corporate history was closely connected to a public-shell transaction completed in 2004. Great Expectations, a Colorado corporation incorporated in 1987, acquired Advaxis in November 2004. The acquiring company changed its name to Advaxis in December of that year and later reincorporated in Delaware. This structure helped establish the corporate vehicle through which the biotechnology business pursued financing, research, and public-market development. The company’s scientific identity came from a platform based on live but attenuated Listeria monocytogenes. The vector was genetically engineered to secrete a fusion protein containing a selected antigen and an adjuvant associated with Listeria’s immune-stimulating properties. Advaxis described the approach as an Lm-LLO immunotherapy platform. The underlying concept was to use the vector to reach antigen-presenting and other immune-system cells, then redirect the resulting T-cell response toward tumor cells bearing the relevant antigen. The platform’s preclinical foundation was associated with research by Yvonne Paterson, a microbiology professor at the University of Pennsylvania. ADXS-HPV became the company’s leading publicly identified clinical program. It was designed to target antigens associated with human papillomavirus and was evaluated in HPV-related diseases, including cervical intraepithelial neoplasia, cervical cancer, and HPV-associated head and neck cancer. In 2009, results from an initial Phase 1 study in patients with metastatic, recurrent, or refractory cervical cancer were published. The study examined adverse effects across increasing dose levels, demonstrated that the attenuated Lm-LLO approach could be administered to human subjects, and established a maximum tolerated dose. Four of thirteen evaluable patients were reported to have experienced increased survival and tumor shrinkage in that early study. Advaxis expanded its research beyond ADXS-HPV. Public descriptions referred to more than fifteen constructs in different stages of development, developed directly or with strategic collaborators. Programs addressed additional oncology settings, including breast cancer and personalized immunotherapies based on individual tumor antigens. Collaborations and research relationships were associated with organizations such as the National Cancer Institute, Cancer Research UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security. The company also investigated applications outside human oncology. Under a cooperative research and development arrangement with the Department of Homeland Security, a pilot proof-of-concept study examined safety in cattle. Separately, Advaxis and the University of Pennsylvania School of Veterinary Medicine began a Phase 1 study of an Lm-LLO-based immunotherapy in canine osteosarcoma. Commercial development was pursued through partnerships as well as internal clinical work. In 2014, Advaxis entered a co-development and commercialization agreement with India’s Biocon for ADXS-HPV in the Indian market. The arrangement was relevant to HPV-associated cancers, particularly cervical cancer, but the company’s programs remained investigational and did not become a broad portfolio of approved commercial medicines. Advaxis subsequently underwent corporate consolidation. A merger with Ayala Pharmaceuticals led to the combined company beginning operations under the Ayala Pharmaceuticals name in January 2023. This transaction ended Advaxis’s period as an independent biotechnology company and makes the brand primarily a historical reference to its cancer-immunotherapy platform, clinical programs, and corporate predecessor.

1. 2023Merger with Ayala Pharmaceuticals

   Following a merger with Ayala Pharmaceuticals, the newly formed company began operations under the Ayala Pharmaceuticals name in January.

   Source
2. 2014Biocon collaboration for India

   Advaxis entered a co-development and commercialization agreement with Biocon for ADXS-HPV in India.

   Source
3. 2009First Phase 1 ADXS-HPV results

   Early clinical results for ADXS-HPV in advanced cervical cancer supported the feasibility and tolerability assessment of the Lm-LLO approach and established a maximum tolerated dose.

   Source
4. 2004Great Expectations acquisition and renaming

   Great Expectations acquired Advaxis, changed its own name to Advaxis, and later completed a Delaware reincorporation.

   Source
5. 2002Official company inception

   Advaxis recorded 1 March 2002 as its official date of inception.

   Source

Clinical-stage cancer-immunotherapy developer using engineered attenuated Listeria monocytogenes vectors to stimulate antigen-specific T-cell responses.

• ADXS-HPVCancer immunotherapy candidate

  ADXS-HPV was Advaxis’s leading investigational Lm-LLO immunotherapy. It used an engineered attenuated Listeria vector to deliver antigens associated with human papillomavirus and stimulate an antigen-directed T-cell response. The program was evaluated in HPV-associated conditions including cervical intraepithelial neoplasia, cervical cancer, and HPV-associated head and neck cancer. It remained a clinical-development candidate rather than an approved, broadly commercialized medicine.

• Lm-LLO immunotherapy platformBiotechnology platform

  Advaxis’s core platform used genetically engineered, attenuated Listeria monocytogenes to secrete antigen-and-adjuvant fusion proteins. The design aimed to stimulate immune cells and focus T-cell activity on tumor-associated antigens. The platform supported multiple oncology constructs, including programs for HPV-related disease, breast cancer, personalized tumor antigens, and experimental veterinary applications.

• Canine osteosarcoma Lm-LLO immunotherapyVeterinary oncology candidate

  Advaxis worked with the University of Pennsylvania School of Veterinary Medicine on a Phase 1 evaluation of an Lm-LLO-based immunotherapy for canine osteosarcoma. The program represented an extension of the company’s platform into veterinary oncology and was investigational rather than a commercial veterinary medicine.

• 2023Merged with Ayala PharmaceuticalsM&A

  Advaxis underwent a corporate transaction that changed its organizational identity and ended its period as an independent biotechnology company.

  What changed. Advaxis merged with Ayala Pharmaceuticals, and the newly formed company began operating under the Ayala Pharmaceuticals name in January 2023.

  Aftermath. Advaxis became a historical corporate and development brand rather than an independent active operating company.

  Source
• 2014Partnered with Biocon for Indian development and commercializationStrategy

  Advaxis sought regional development and commercialization support for ADXS-HPV in a market with a significant burden of HPV-associated disease.

  What changed. The company entered a co-development and commercialization agreement with Biocon covering India.

  Aftermath. The agreement expanded the intended geographic scope of the ADXS-HPV program, while the therapy remained investigational.

  Source

• 2023Advaxis merged with Ayala Pharmaceuticals

  The merger changed the company’s corporate identity and structure. The newly formed company began operations under the Ayala Pharmaceuticals name in January 2023.

  M&A
  Source
• 2014Advaxis entered a co-development and commercialization agreement with Biocon for ADXS-HPV in India

  The agreement addressed development and commercialization of the ADXS-HPV therapeutic in India, including the market for HPV-associated cancers such as cervical cancer.

  M&AOther
  Source

1. Advaxis